February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
December 2, 2021To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...view
March 22, 2022The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...view
June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view